<DOC>
	<DOCNO>NCT00522379</DOCNO>
	<brief_summary>The purpose study show Rotigotine dose response four dos Rotigotine use L-dopa treat advanced stage Parkinson 's disease .</brief_summary>
	<brief_title>Trial Assess Parkinson 's Disease ( PD ) Symptom Control Four Doses Rotigotine Transdermal Patch</brief_title>
	<detailed_description>To maintain treatment blind , two different active patch size use ( 10 cm^2 &amp; 20 cm^2 ) . Placebo patch match accord size appearance . During trial subject apply three patch , active placebo , achieve assign daily dose .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>PD great 3 year Stable dose Ldopa symptom adequately control `` '' time Able willing complete diary specific day Previous use rotigotine Neupro Atypical Parkinson 's syndrome Pallidotomy Thalamotomy Deep brain stimulation Fetal tissue transplant Dementia Psychosis Hallucinations Epilepsy Renal hepatic dysfunction Clinically relevant cardiac dysfunction Symptomatic orthostatic hypotension Skin sensitivity adhesives unresolved contact dermatitis History chronic alcohol drug abuse Pregnant childbearing potential Impulse control disorder</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>rotigotine</keyword>
	<keyword>patch</keyword>
	<keyword>transdermal</keyword>
	<keyword>dopamine agonist</keyword>
	<keyword>time</keyword>
	<keyword>Neupro</keyword>
</DOC>